Archives — April 2017 back to current month (10)
Maxim Group noted that data from Zynerba's Phase 2 proof of concept trial will be released in the third quarter; positive data would set the stage for Phase 3 trials.
Maxim Group recently initiated coverage of VistaGen Therapeutics, citing its progress on development of a fast-acting therapy to treat major depressive disorders.
Positive results in a Phase 1b trial of DURECT Corp.'s candidate for the treatment of nonalcoholic steatohepatitis (NASH), which were presented at the 2017 International Liver Congress, prompted comments from a pair of analysts.
The Small-Cap Biotech Watchlist, composed of 20 companies targeting a range of indications including blood cancers and solid tumors, irritable bowel disease and orphan diseases, has posted a modest gain since the first of the year.
Positive results from RepliCel's Phase 1 trial for the treatment of aging and sun-damaged skin follow the release in the past few weeks of positive data from trials for chronic tendon problems and for hair loss.
The 4th annual AlphaNorth Capital Conference brought together over 40 emerging growth companies with top investors. In this interview with Streetwise Reports, Steve Palmer, founder and president of AlphaNorth Asset Management and a co-organizer of the conference, discusses a diverse group of companies that were selected to attend the conference, including three biotech companies.
With the granting of a new patent in Japan for its lead compound, RXI-109, RXI Pharmaceuticals has strengthened its reach in Asian markets and enhanced the protections surrounding its proprietary RNAi platform.
Biotech may be the last great bastion of stock picking, posits Eden Rahim, who manages the Toronto-based Next Edge Bio-Tech Plus Fund. The fund is up 40% in the last 12 months. In this interview with The Life Sciences Report, Rahim provides his view of the sector and profiles four companies he believes may have great upside.
In a milestone for South San Francisco-based VistaGen Therapeutics, the European Patent Office (EPO) has issued a Notice of Intention to grant the company patents for its antidepressant prodrug, AV-101.
Zynerba Pharmaceuticals specializes in developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Devon, Pennsylvania-based company's Q4/16 financial results disclose a substantial cash kitty of ~$78M available to fund its pipeline of medical marijuana products, ZYN001 and ZYN002.
|"VIVs recent distribution deals illustrate demand for its technology."|
|"PMN is looking to outlicense PMN310 after the Phase 1 study."|
|"DRRX intends to start a NASH trial as soon as H1/19."|